Suchen Sie nach Informationen zu Alkermes US-Zentrale? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
Driven by Passion. Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our …
https://www.alkermes.com/about-us
Discover Alkermes. Alkermes is focused on developing innovative medicines that aim to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated global biopharmaceutical company, we apply our scientific expertise and proprietary technologies to develop products that are designed to make a ...
https://www.alkermes.com/contact-us
U.S. Medical Information. Healthcare professionals, patients and caregivers with questions can reach Alkermes Medical Information by phone at 1-888-235-8008 (Direct: 1-571-599-2702) Monday through Friday between 9 a.m. and 7 p.m. ET or by sending an email to [email protected]. U.S. healthcare professionals are encouraged to visit the ...
https://www.alkermes.com/responsibility/alkermes-inspiration-grants-2022
2022 Program Overview. Alkermes will accept applications for the Alkermes Inspiration Grants ® program beginning on June 15, 2022. Now in its sixth year, this competitive grants program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.
https://www.alkermes.com/medicines-and-focus/us-third-party-medicines
U.S. Medicines Using Alkermes' Technologies. We have granted licenses under our proprietary technologies to enable third parties to develop, commercialize and, in some cases, manufacture medicines for which we receive royalties and/or manufacturing revenues. Such arrangements in the U.S. include the following:
https://craft.co/alkermes
Alkermes revenue breakdown by geographic segment: 83.9% from UNITED STATES, 16.0% from REST OF WORLD and 0.2% from Other. Alkermes Cybersecurity Score. Cybersecurity rating Premium dataset. C. 72/100. ... Alkermes's key executives are Shane Cooke, Jim Frates and Madeline Coffin. How many employees does Alkermes have? Alkermes has …
https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-us-food-and-drug-administration-acceptance
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases and oncology. The company has a diversified commercial product portfolio and a clinical pipeline of product candidates for diseases that include schizophrenia, depression, addiction ...
https://www.reuters.com/business/healthcare-pharmaceuticals/alkermes-schizophrenia-drug-gets-us-fda-nod-2021-06-01/
Alkermes Plc (ALKS.O) said on Tuesday the U.S. Food and Drug Administration (FDA) had approved its treatment, Lybalvi, for schizophrenia and bipolar I disorder.
https://www.reuters.com/article/us-alkermes-plc-fda-idUSKBN27X1GI
Drugmaker Alkermes said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for schizophrenia and bipolar disorder, citing concerns related to a tablet coating ...
https://finance.yahoo.com/news/beat-store-alkermes-alks-earnings-162504536.html
Alkermes’ earnings surprise history has been excellent so far, having surpassed expectations in each of the trailing four quarters, with an average beat of 350.48%. In the last reported quarter ...
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Alkermes US-Zentrale gefunden haben.
